TEL AVIV, Israel, August 27 /PRNewswire-FirstCall/ -- Notice is hereby given that the 2007 Annual General Meeting (the "Annual Meeting") of the Shareholders of Rosetta Genomics Ltd. (NASDQ:ROSG) (the "Company"), an Israeli company, will be held at the offices of Yigal Arnon & Co., Azrieli Center, Round Tower, 47th floor, Tel Aviv, Israel on Monday, September 24, 2007, at 11:00 a.m. (Israel time) for the following purposes:
1. To approve the appointment of Kost, Forer, Gabbay & Kasierer (a member of Ernst & Young Global), as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2007 and its service as the Company's independent registered public accounting firm until the next Annual General Meeting and to authorize the Board of Directors of the Company, upon recommendation of the Audit Committee, to fix remuneration of said firm; and
2. To report on the business of the Company for the year ended December 31, 2006 (including a review of the 2006 audited consolidated financial statements).
The affirmative vote of the holders of a majority of the voting power represented at the meeting in person or by proxy, and voting thereon, is necessary for the approval of the first proposal.
Shareholders of record at the close of business on August 31, 2007, are entitled to notice of, and to vote at, the Annual Meeting. All shareholders are cordially invited to attend the Annual Meeting in person.
A proxy statement describing the matter to be voted upon at the meeting with a proxy card enabling the Shareholders to indicate their vote on such matter will be mailed on or around September 2, 2007 to all Shareholders entitled to vote at the Annual Meeting and is also available on the Company's website at www.rosettagenomics.com and on the SEC's website at www.sec.gov.
Shareholders who do not expect to attend the Meeting in person are requested to mark, date, sign and mail the proxy card to the office of the Company's transfer agent, American Stock Transfer & Trust Company located at 6201 15th Ave, Brooklyn, NY 11219, not less than twenty four (24) hours before the time fixed for the Annual Meeting in order to be qualified to participate in meeting.
About Rosetta Genomics
Rosetta Genomics is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases.
Contact: Media Alan Zachary T: +1-(312)-944-6784 media@rosettagenomics.com Investors Juliane Snowden T: +1-(212)-213-0006 investors@rosettagenomics.com
Rosetta Genomics LtdCONTACT: Contact: Media, Alan Zachary, T: +1-(312)-944-6784,media@rosettagenomics.com; Investors, Juliane Snowden, T:+1-(212)-213-0006, investors@rosettagenomics.com
